Aquis Stock Exchange Weekly Highlights 6/10/23

Tap Global Group Plc announced its intention to launch in the United States, via its wholly owned subsidiary Tap Americas, through a partnership with Zero Hash LLC (“Zero Hash”), a Chicago-based B2B2C crypto infrastructure platform.

Highlights:

• Tap will operate under Zero Hash’s existing regulatory coverage in the US
• Tap will operate under Zero Hash’s existing regulatory coverage in the US
• Tap’s US users will be offered access to 24 digital assets, including BTC, ETH, XRP and USDC
• Tap’s US application is expected to launch in Q4 2023 to a significant waiting list
• Launch in the US to underpin continued expansion of Tap’s growing user base

Capital for Colleagues PLC announced an investment update in respect of the quarter ended 31 August 2023.

Key Developments in the quarter:

• The Company received the second of 5 annual tranches of consideration for the sale of its ‘A’ ordinary shares in The Homebuilding Centre (Holdings) Limited (‘HBC’). The consideration for the second tranche amounted to £107,999 in cash, a premium to the agreed minimum payment of £50,000, reflecting successful ongoing trading at HBC.

• The Company received the second of 5 annual tranches of consideration for the sale of its ‘A’ ordinary shares in The Homebuilding Centre (Holdings) Limited (‘HBC’). The consideration for the second tranche amounted to £107,999 in cash, a premium to the agreed minimum payment of £50,000, reflecting successful ongoing trading at HBC.
• Bright Ascension Limited has been selected to lead onboard and ground software development for the 3-year OS2-VOLT mission. The OS2-VOLT mission has a total value of around €12.0 million and is designed to evaluate and test radical new real-time techniques and technologies in low Earth orbit.
• The Company has converted £250,000 of its £412,000 of outstanding loans to The Real Outdoor Xperience (‘ROX’) - formerly South Cerney Outdoor Limited - into 250,000 A ordinary shares in ROX. The A ordinary shares, which give C4C preferential rights in respect of dividends and the return of capital, will be bought back (subject to certain conditions being met) by ROX in 5 annual tranches of £50,000 each.
• To reflect the growth at Computer Application Services Limited (‘CAS’) and to prudently rebalance this element of the Company’s investment portfolio, C4C has disposed of part of its holding of CAS ordinary shares to Bill Ainscough, a non-executive Director of the Company, and TJ Morris Limited, a significant shareholder in C4C, in equal proportions, for total cash consideration of £754,000.
• The Company currently has cash balances of £1,985,636 and no debt.

Read more…

Invinity Energy Systems plc announced a 1.1 MWh sale to Taiwan's National Applied Research Laboratories ("NARLabs"). The project will see five Invinity VS3 vanadium flow batteries ("VFBs") with a combined capacity of 1.1 MWh installed inside a building at the NARLabs laboratory in Taipei. The VFBs will be used to offset electricity use at the facility during peak times and provide back-up in the event of a power outage. NARLabs will also perform validation testing on Invinity's technology with the intention of verifying the performance and safety of the Company's batteries in order that they may be specified into future Taiwanese energy infrastructure projects. Delivery of the Invinity batteries is expected to commence in Q4 2023. The contract was included as part of the Company's Base category in its most recently disclosed commercial pipeline. Read more…

EDX Medical Group plc announced that it has entered into a strategic agreement with Guardant Health Inc. (NASDAQ: GH), a leading precision oncology company, to distribute Guardant Health's blood-based liquid biopsy tests in certain market sectors in the U.K. and several Nordic countries. Under the agreement, EDX Medical will distribute the Guardant360® CDx test for genomic testing in advanced cancer and the Guardant Reveal™ test for residual disease and recurrence detection in early-stage cancer to the private healthcare sector in the U.K. The company will also distribute Guardant360 CDx to public and private sectors in Sweden, Denmark, Norway, Finland and Iceland (Nordics).

Dr, Mike Hudson, chief executive of EDX Medical, said: "I'm delighted to be working with the scientific leaders at Guardant Health. This agreement provides our clients with access to world-class genomic testing products and the opportunity to join a group of thought leaders in personalised medicine." Read more…

Hydrogen Future Industries plc announced the issue of 1,750,000 new ordinary shares at a price of 10 pence per new ordinary share and warrants over 875,000 new ordinary shares with an exercise price of 12 pence per new ordinary share as the second tranche of consideration payable to the vendors of various patents acquired by the Company as announced on 5 October 2022.

Daniel Maling, Executive Director of HFI, commented: "We at HFI are pleased to have completed the deferred component of the IP acquisition at an effective share price of 10 pence. The suite of international patents is derived from over 12 years of valuable research by Tim Blake including the key aspects of our novel green hydrogen production system. The wind turbine component, which had previously demonstrated increased energy generation of over 300% in wind tunnel testing, is now delivering similar performance data in Montana where we have installed a 1 metre prototype.” Read more…